Elizabeth Kemmerer

Array ( [id] => 17036726 [patent_doc_number] => 20210253684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA [patent_app_type] => utility [patent_app_number] => 17/138691 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451515 [patent_doc_number] => 20230192793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IL-37 FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/787168 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20241001 [patent_doc_number] => 12421309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Anti-TM4SF4 antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 17/299156 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 10367 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19256876 [patent_doc_number] => 12016905 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Pharmaceutical composition for prevention or treatment of preterm birth [patent_app_type] => utility [patent_app_number] => 17/108485 [patent_app_country] => US [patent_app_date] => 2020-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 5678 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710484 [patent_doc_number] => 20210077631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => COMPOSITIONS AND METHODS FOR MODIFYING THE SURFACE OF CELLS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/107107 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17107107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16949470 [patent_doc_number] => 20210208161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => CCL24 as a Diagnostic and Therapeutic Target for Breast Cancer [patent_app_type] => utility [patent_app_number] => 17/102633 [patent_app_country] => US [patent_app_date] => 2020-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057983 [patent_doc_number] => 20220389069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => COMPOSITIONS AND METHODS REGULATING FOLLICULOGENESIS FOR THE TREATMENT OF OVARIAN SENESCENCE [patent_app_type] => utility [patent_app_number] => 17/775043 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711904 [patent_doc_number] => 20210079051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/094968 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004976 [patent_doc_number] => 20220363742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => TREATMENTS OF MENIERE'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/771697 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20479375 [patent_doc_number] => 12527839 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Treatments for systemic sclerosis [patent_app_type] => utility [patent_app_number] => 17/774383 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 82969 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036737 [patent_doc_number] => 20210253695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => USE OF SIGLEC-7 OR SIGLEC-9 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/080132 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761116 [patent_doc_number] => 20210106697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => Anti-Polyethylene Glycol (PEG) Antibody Mouse Model for Rigorous Assessment of PEG-Based Therapies [patent_app_type] => utility [patent_app_number] => 17/071653 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18006334 [patent_doc_number] => 20220365100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH LARGE MOLECULE MODULATORS [patent_app_type] => utility [patent_app_number] => 17/763881 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982642 [patent_doc_number] => 20220348678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING DIABETIC RETINOPATHY [patent_app_type] => utility [patent_app_number] => 17/763989 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17991304 [patent_doc_number] => 20220357341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH SMALL MOLECULE MODULATORS [patent_app_type] => utility [patent_app_number] => 17/763863 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16763531 [patent_doc_number] => 20210109112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => METHOD OF TREATING AND PROGNOSING SCOLIOTIC PATIENT SUBGROUPS [patent_app_type] => utility [patent_app_number] => 17/015006 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710438 [patent_doc_number] => 20210077585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => METHOD OF TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-RELATED IMMUNE ADVERSE EFFECTS [patent_app_type] => utility [patent_app_number] => 17/013121 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673150 [patent_doc_number] => 20210061913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => PDL-1 INHIBITORS IN TREATMENT OF PULMONARY VASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/006452 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673108 [patent_doc_number] => 20210061871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => Modified N-810 and Methods Therefor [patent_app_type] => utility [patent_app_number] => 17/006184 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940288 [patent_doc_number] => 12312410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Anti-CD39 antibodies [patent_app_type] => utility [patent_app_number] => 17/283553 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 23 [patent_no_of_words] => 32025 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283553 [rel_patent_id] =>[rel_patent_doc_number] =>)